TLE3 loss confers AR inhibitor resistance by facilitating GR-mediated human prostate cancer cell growth
Sander Palit(The Netherlands Cancer Institute), Michiel S. van der Heijden(The Netherlands Cancer Institute)
Cited by 38
Related Papers
Preoperative ipilimumab plus nivolumab in locoregionally advanced urothelial cancer: the NABUCCO trial
|Nature Medicine|2020|395
The Tumor Immune Landscape and Architecture of Tertiary Lymphoid Structures in Urothelial Cancer
|Frontiers in Immunology|2021|40
A kinome-centered CRISPR-Cas9 screen identifies activated BRAF to modulate enzalutamide resistance with potential therapeutic implications in BRAF-mutated prostate cancer
|Scientific Reports|2021|17